![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Three Phase I Drug Interaction Studies Investigating the Next-Generation Maturation Inhibitor GSK3640254 With Oral Contraceptive Ethinyl Estradiol/Levonorgestrel,
Dolutegravir, and Tenofovir Alafenamide/Emtricitabine
|
|
|
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs Virtual Meeting, September 28-30, 2020
Reported by Jules Levin
1GlaxoSmithKline, Upper Providence, PA, USA; 2ViiV Healthcare, Branford, CT, USA; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA
Correspondence to Teodora Pene Dumitrescu: teodora.x.pene-dumitrescu@gsk.com
![0930201](../images/093020/093020-4/0930201.gif)
![0930202](../images/093020/093020-4/0930202.gif)
![0930203](../images/093020/093020-4/0930203.gif)
![0930204](../images/093020/093020-4/0930204.gif)
![0930205](../images/093020/093020-4/0930205.gif)
![0930206](../images/093020/093020-4/0930206.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|